

Risperidone Long-acting Injection (Risperdal Consta®)

Place of Service

Infusion Center Administration
Home Infusion Administration
Office Administration
Outpatient Facility Administration

HCPCS: J2794 per 0.5 mg

Conditions listed in policy (see criteria for details):

- [Bipolar disorder](#)
- [Schizophrenia](#)

AHFS therapeutic class: Atypical antipsychotic

Mechanism of action: Risperidone is dopamine type 2 and serotonin type 2 (5-HT₂) receptor antagonist.

(1) Special Instructions and Pertinent Information

Covered under the Medical Benefit, please submit clinical information for prior authorization review via fax.

(2) Prior Authorization/Medical Review is required for the following condition(s)

All requests for Risperdal Consta® (risperidone long-acting) for conditions NOT LISTED in section 3 must be sent for clinical review and receive authorization prior to drug administration or claim payment.

Diagnoses other than schizophrenia and bipolar disorder

- Regimen is a continuation of inpatient hospital therapy

Covered Doses

Up to 50 mg IM injection every 2 weeks

Coverage Period

Indefinite

(3) The following condition(s) DO NOT require Prior Authorization/Preservice

All requests for Risperdal Consta® (risperidone long-acting) for conditions NOT LISTED in section 3 must be sent for clinical review and receive authorization prior to drug administration or claim payment.

Bipolar disorder or Schizophrenia

Covered Doses

Up to 50 mg IM injection every 2 weeks

ICD-10:

F20.0-F29
F30.10-F30.9,
F31.0-F31.9,
F33.8, F34.8, F34.9

(4) This Medication is NOT medically necessary for the following condition(s)

Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Code § 1367.21, including objective evidence of efficacy and safety are met for the proposed indication.

Please refer to the Provider Manual and User Guide for more information.

(5) Additional Information

How Supplied:

12.5 mg, 25 mg, 37.5 mg, 50 mg Intramuscular Powder for Suspension, Extended Release

Patients should be continued on an oral antipsychotic for 3 weeks after first IM injection and then tapered off oral over 3-4 days.

(6) References

- AHFS®. Available by subscription at <http://www.lexi.com>
- DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
- Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong SH; (Systematic Review). The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020 Sep 1;177(9):868-872.
<https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841>
- McClellan J, Stock S, American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia. J Am Acad Child Adolescent Psychiatry 2013;52:976-90.
- Risperdal Consta® (risperidone). [Prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 1/2019.

(7) Policy Update

Date of last revision: 2Q2021

Date of next review: 1Q2022

Changes from previous policy version:

- No clinical change to policy following revision.